This suggests that these targets, particularly ATF3, may be key effectors in the synergistic anti-MM apoptotic response to the combination, and further identifies ATF3, DDIT3/CHOP, and DNAJB1 mRNA are biomarkers of response to this new drug combination. The gene discussed is DNAJB1; the disease is Miyoshi myopathy.